EquipNet to Discuss Asset Management Systems at Interphex 2014
News Mar 14, 2014
Experts from EquipNet Inc. will be on hand at Interphex 2014 (18-20 March in New York City) to demonstrate and discuss the company’s unique asset management solution.
The industry-leading company is dedicated to the pharmaceutical, biotechnology and chemical markets; helping businesses redeploy or sell idle or surplus analytical instruments, process pilot, laboratory, and packaging equipment.
Asset management has evolved in recent years, with surveys showing companies have, on average, 5% of their assets lying idle. EquipNet has been at the forefront of these changes and now offers its clients a range of workflow and management solutions to aid redeployment or sale of business assets.
Their web-based system, ARMS™ (Asset Redeployment Management System) sits behind a company’s firewall, efficiently tracking and facilitating internally redeployment of equipment that is not being used in its current location.
Where an asset can not be relocated, it can be moved through into one of several sales channels. In every case, EquipNet specialists provide expert knowledge and proven project management skills to deliver a complete service package.
Ben Potenza, VP Marketing at EquipNet, said, “Working with both multinational enterprises as well as small and medium sized companies with a single facility, we provide our clients with options to redeploy or sell surplus plant and equipment to gain a real return on their investment.”
To find out more about EquipNet’s asset management expertise and how pharmaceutical industry companies have benefited, visit EquipNet on Booth #1239.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018
18th International Conference and Exhibition on Analytical & Bioanalytical Chromatographic Techniques
Nov 02 - Nov 03, 2017